Results 131 to 140 of about 1,336,088 (341)

Focal Spot, Summer 2002 [PDF]

, 2002
https://digitalcommons.wustl.edu/focal_spot_archives/1091/thumbnail ...

core   +1 more source

Emerging role of ARHGAP29 in melanoma cell phenotype switching

Molecular Oncology, EarlyView.
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster, Melanie Kappelmann‐Fenzl, Anja Katrin Bosserhoff, Nicole Rachinger   +3 more
wiley   +1 more source

Phase i study of \u27dose-dense\u27 pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma. [PDF]

, 2011
BACKGROUND: This phase I study investigates the feasibility of carboplatin plus dose-dense (q2-week) pemetrexed given concurrently with radiotherapy (XRT) for locally advanced and oligometastatic non-small cell lung cancer (NSCLC).
Axelrod, Rita, Curran, Walter J, Denittis, Albert, Gilman, Paul, Machtay, Mitchell, Meyer, Thomas, Shen, Xinglei, Treat, Joseph, Werner-Wasik, Maria   +8 more
core   +1 more source

Information Needed to Conduct First-in-Human Oncology Trials in the United States: A View from a Former FDA Medical Reviewer [PDF]

, 2010
Adrian M. Senderowicz
openalex   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

Patient/Family Education for Newly Diagnosed Pediatric Oncology Patients [PDF]

, 2016
There is a paucity of data to support evidence-based practices in the provision of patient/family education in the context of a new childhood cancer diagnosis.
Ahern, JoAnn, Barakat, Lamia P., Bhatia, Smita, Bingen, Kristin M., Bondurant, Patricia G., Cohn, Susan L., Dobrozsi, Sarah K., Haugen, Maureen, Herring, Ruth Anne, Hockenberry, Marilyn, Hooke, Mary C., Landier, Wendy, Martin, Melissa, Murphy, Kathryn, Newman, Amy R., Rodgers, Cheryl C., Ruccione, Kathleen S., Sullivan, Jeneane, Weiss, Marianne E., Withycombe, Janice, Yasui, Lise   +20 more
core   +1 more source

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source

The association of diabetes mellitus and routinely collected patient‐reported outcomes in patients with cancer. A real‐world cohort study

Cancer Medicine
Objective Current studies have indicated that diabetes mellitus (DM) is highly prevalent in patients with cancer, but there is little research on consequences on the well‐being of patients during cancer treatment. This analysis evaluates the relationship
Dominik J. Ose, Emmanuel Adediran, Bayarmaa Mark, Krista Ocier, William A. Dunson JR, Cindy Turner, Belinda Taylor, Kim Svoboda, Andrew R. Post, Jennifer Leiser, Howard Colman, Cornelia M. Ulrich, Mia Hashibe   +12 more
doaj   +1 more source

Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in clinical trials supporting US Food and Drug Administration (FDA) approval of orphan vs. non-orphan drugs [PDF]

, 2017
C. Moltó Valiente, Ariadna Tibau, Alberto Ocaña, Arnoud J. Templeton, L.P. del Carpio, Joseph C. Del Paggio, Agustí Barnadas, Christopher M. Booth, Eitan Amir   +8 more
openalex   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source